|
International Organization of MS Nurses |
 |
 |
 |
|
Written by Administrator2
|
|
- LETTER TO IOMSN MEMBERS
As we begin 2015, it is my hope that each of you will experience good health and happiness in the months to come. Read more.
- OUR CONDOLENCES TO THE FAMILY OF PAULINE WELDON
IOMSN is sad to announce the passing of MS nurse Pauline Weldon. She worked with Dr. Jock Murray at the founding of the Dalhousie MS research unit. She also played a leading role in nursing including President of the Canadian Neurological Nurses Association and in IOMSN and in CMSC. She retired about 10 years ago to her family farm but continued nursing at local healthcare facilities. There is no funeral but in the spring there will be a celebration of her life.
- MS BLUEPRINT, A UNIQUE NEW TOOL FOR THE MS COMMUNITY, HAS LAUNCHED!
The International Organization of Multiple Sclerosis Nurses (IOMSN) has partnered with Biogen Idec to launch MS Blueprint™, a program to encourage those impacted by MS to set goals, create personalized activity plans called MS Blueprints, and take small steps to attain a more positive life. Learn more.
- FDA PERMITS MARKETING OF URINARY PROSTHESIS DEVICE FOR WOMEN
Release Date: October 14, 2014
The U.S. Food and Drug Administration today allowed marketing of the inFlow Intraurethral Valve-Pump, a replaceable urinary prosthesis for use in female adults who cannot contract the muscles necessary to push urine out of the bladder (impaired detrusor contractility or IDC). Learn more.
- ACUTE NEUROLOGIC ILLNESS WITH FOCAL LIMB WEAKNESS OF UNKNOWN ETIOLOGY IN CHILDREN
In September, the Centers for Disease Control and Prevention (CDC) issued a Health Advisory to healthcare professionals nationwide to be vigilant for and report cases of neurologic illnesses associated with limb weakness that meet the criteria of its case definition. Learn more.
- PEGYLATED INTERFERON BETA-1A (PLEGRIDY) – CLINICIAN INFORMATION
Generic: Peginterferon Beta-1a
Brand name: Plegridy
US FDA Approved: August 2014
- MS COALITION: The Use of Disease-Modifying Therapies in MS
The member organizations of the Multiple Sclerosis Coalition have collaborated to summarize the current evidence about disease modification in multiple sclerosis (MS) and to provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people.
- Counseling Points: SUMMER 2014 Volume 10, Number 1
Management of MS Through the Life Stages
- MOVING FORWARD:
Adherence to Therapy & the Role of Nursing in MS
- WEBINAR: Caring for the Patient with MS
Please join us on Monday - January 26, 2015 at 8PM ET for our last webinar on Caring for the Patient with MS. The discussion will focus on Psychosocial Considerations in MS and will be presented by :
June Halper, MSN, APN-C, FAAN, MSCN
Nurse Practitioner
Exec. Director - IOMSN/MSNICB
CEO - CMSC
Hackensack, NJ
This event is awarded 1.0 CEU.
| 
|
- iPointofCare: Managing Patients with MS
 This is an innovative evidence-based, clinical resource for MS specialists, providing answers to clinical questions at or near the "point-of-care" - where and when clinicians need it: in the office, in the exam room, on computers, tablets or smart phones. All material is peer-reviewed and faculty-approved.
Release Date: January 25, 2013
Valid Through: January 30, 2015
|
|
